HSTOQ (Histogen) ROE % Adjusted to Book Value: -522.88% (As of Sep. 2023)


HSTOQ Histogen Inc HSTOQ
12 GF Score
Price $0.00
View Full Analysis

What is Histogen ROE % Adjusted to Book Value?

Histogen HSTOQ +316.67% 12 ROE % Adjusted to Book Value is -522.88% as of Sep. 2023. GuruFocus rates HSTOQ with a GF Score™ of 12/100.

Histogen's ROE % for the quarter that ended in Sep. 2023 was -209.15%. Histogen's PB Ratio for the quarter that ended in Sep. 2023 was 0.40. Histogen's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -522.88%.

Histogen ROE % Adjusted to Book Value Related Terms

Histogen ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Histogen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Histogen ROE % Adjusted to Book Value Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
0.00 0.00 -131.95 -238.68

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -259.39 -299.36 -234.28 -245.61 -522.88

HSTOQ vs GLMD, BLCM, NBY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Histogen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Histogen ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Histogen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Histogen's ROE % Adjusted to Book Value falls into.


HSTOQ
12GF Score
Histogen Inc HSTOQ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Histogen ROE % Adjusted to Book Value Calculation

Histogen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-59.67% / 0.25
=-238.68%

Histogen's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-209.15% / 0.40
=-522.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -522.88% mean?
Histogen (HSTOQ) has a ROE % Adjusted to Book Value of -522.88% as of Sep. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Histogen and its competitors.
Is Histogen's ROE % Adjusted to Book Value too high?
Histogen's current ROE % Adjusted to Book Value is -522.88%. Overall, Histogen has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Histogen's ROE % Adjusted to Book Value compare to GLMD and BLCM?
Histogen's ROE % Adjusted to Book Value of -522.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Histogen and its competitors. Histogen's current ROE % Adjusted to Book Value is -522.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Histogen stock overvalued right now?
Histogen (HSTOQ) has a current ROE % Adjusted to Book Value of -522.88%. The current ROE % Adjusted to Book Value is -522.88%. Histogen's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Histogen (HSTOQ), the current ROE % Adjusted to Book Value is -522.88% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Histogen Business Description

Address 10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
12GF Score

Get the complete analysis for HSTOQ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price